GLYCOPROTEIN GP116 OF HUMAN CYTOMEGALOVIRUS CONTAINS EPITOPES FOR STRAIN-COMMON AND STRAIN-SPECIFIC ANTIBODIES

被引:103
作者
MEYER, H
SUNDQVIST, VA
PEREIRA, L
MACH, M
机构
[1] UNIV ERLANGEN NURNBERG, INST KLIN & MOLEK VIROL, LOSCHGESTR 7, W-8520 ERLANGEN, GERMANY
[2] UNIV CALIF SAN FRANCISCO, SCH DENT, DIV ORAL BIOL, SAN FRANCISCO, CA 94143 USA
[3] NATL BACTERIOL LAB, DEPT VIROL, S-10521 STOCKHOLM, SWEDEN
[4] KAROLINSKA INST, S-10401 STOCKHOLM 60, SWEDEN
关键词
D O I
10.1099/0022-1317-73-9-2375
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Glycoprotein gp116 of human cytomegalovirus (HCMV) is a target for neutralizing antibodies. Gp116 is a component of the gCI complex which consists of gp58 and gp116. Like its homologue, glycoprotein B of herpes simplex virus type 1, gp116 contains a highly antigenic region in the N-terminal part of the molecule, between amino acids 28 and 84. Prokaryotic expression plasmids and synthetic peptides were used to define binding sites for mouse and human monoclonal antibodies (MAbs) as well as HCMV convalescent sera. Site I, located between amino acids 68 and 77, contains an epitope recognized by the human MAb C23, which is capable of neutralizing HCMV independently of complement and the site is conserved between HCMV strains. Of HCMV-positive human sera, 53% recognized site I. Site II was mapped using mouse MAbs as well as human sera. It is located between residues 50 and 54, an area which is not conserved between strains AD169 and Towne, the two laboratory strains of known sequence. Strain-specific antibodies were detected in 25% of human sera. Site II-specific antibodies, purified from human sera by affinity chromatography, were found to be incapable of neutralizing HCMV in tissue culture.
引用
收藏
页码:2375 / 2383
页数:9
相关论文
共 49 条
[1]   FINE SPECIFICITY OF CELLULAR IMMUNE-RESPONSES IN HUMANS TO HUMAN CYTOMEGALOVIRUS IMMEDIATE-EARLY 1-PROTEIN [J].
ALP, NJ ;
ALLPORT, TD ;
VANZANTEN, J ;
RODGERS, B ;
SISSONS, JGP ;
BORYSIEWICZ, LK .
JOURNAL OF VIROLOGY, 1991, 65 (09) :4812-4820
[2]   A RAPID MICRONEUTRALIZATION ASSAY FOR THE MEASUREMENT OF NEUTRALIZING ANTIBODY REACTIVE WITH HUMAN CYTOMEGALO-VIRUS [J].
ANDREONI, M ;
FAIRCLOTH, M ;
VUGLER, L ;
BRITT, WJ .
JOURNAL OF VIROLOGICAL METHODS, 1989, 23 (02) :157-167
[3]   COMPLEMENT-INDEPENDENT NEUTRALIZING MONOCLONAL-ANTIBODY WITH DIFFERENTIAL REACTIVITY FOR STRAINS OF HUMAN CYTOMEGALO-VIRUS [J].
BABOONIAN, C ;
BLAKE, K ;
BOOTH, JC ;
WIBLIN, CN .
JOURNAL OF MEDICAL VIROLOGY, 1989, 29 (02) :139-145
[4]   A MAJOR NEUTRALIZING DOMAIN MAPS WITHIN THE CARBOXYL-TERMINAL HALF OF THE CLEAVED CYTOMEGALOVIRUS-B GLYCOPROTEIN [J].
BANKS, T ;
HUO, B ;
KOUSOULAS, K ;
SPAETE, R ;
PACHL, C ;
PEREIRA, L .
JOURNAL OF GENERAL VIROLOGY, 1989, 70 :979-985
[5]   THE AMINO TERMINUS OF HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN-B CONTAINS EPITOPES THAT VARY AMONG STRAINS [J].
BASGOZ, N ;
QADRI, I ;
NAVARRO, D ;
SEARS, A ;
LENNETTE, E ;
YOUNGBLOM, J ;
PEREIRA, L .
JOURNAL OF GENERAL VIROLOGY, 1992, 73 :983-988
[6]   HUMAN CYTOMEGALOVIRUS-SPECIFIC CYTO-TOXIC T-CELLS - RELATIVE FREQUENCY OF STAGE-SPECIFIC CTL RECOGNIZING THE 72-KD IMMEDIATE EARLY PROTEIN AND GLYCOPROTEIN-B EXPRESSED BY RECOMBINANT VACCINIA VIRUSES [J].
BORYSIEWICZ, LK ;
HICKLING, JK ;
GRAHAM, S ;
SINCLAIR, J ;
CRANAGE, MP ;
SMITH, GL ;
SISSONS, JGP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (03) :919-931
[7]   CELL-SURFACE EXPRESSION OF HUMAN CYTOMEGALOVIRUS (HCMV) GP55-116 (GB) - USE OF HCMV-RECOMBINANT VACCINIA VIRUS-INFECTED CELLS IN ANALYSIS OF THE HUMAN NEUTRALIZING ANTIBODY-RESPONSE [J].
BRITT, WJ ;
VUGLER, L ;
BUTFILOSKI, EJ ;
STEPHENS, EB .
JOURNAL OF VIROLOGY, 1990, 64 (03) :1079-1085
[9]   PROCESSING OF THE GP55-116 ENVELOPE GLYCOPROTEIN COMPLEX (GB) OF HUMAN CYTOMEGALO-VIRUS [J].
BRITT, WJ ;
VUGLER, LG .
JOURNAL OF VIROLOGY, 1989, 63 (01) :403-410
[10]   ANALYSIS OF INTERSTRAIN VARIATION IN CYTOMEGALOVIRUS GLYCOPROTEIN-B SEQUENCES ENCODING NEUTRALIZATION-RELATED EPITOPES [J].
CHOU, SW ;
DENNISON, KM .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) :1229-1234